CLINICAL TRIALS PROFILE FOR SIGNIFOR LAR

All Clinical Trials for SIGNIFOR LAR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01469572 ↗	Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases	Completed	Novartis	Phase 1	2011-12-01	The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has spread to the liver. Both everolimus or radioembolization are considered "standard of care" regimens in patients with liver lesions from neuroendocrine tumors. However, the use of the combination of everolimus and radioembolization has not been formally evaluated in the setting of a clinical trial. Pasireotide is a medication that is intended to block the hormonal secretions from the neuroendocrine tumors. This study is divided into two parts. In the first part, the aim of the study is to determine the safety of combining everolimus, pasireotide, and radioembolization. For this part of the study the investigators will enroll up to 18 patients. After the investigators confirm the safety of the combination, they will conduct the second part of the study which will focus on evaluating the effectiveness of the combination. For this part of the study the investigators intend to enroll a total of 37 patients.
NCT01469572 ↗	Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases	Completed	Emory University	Phase 1	2011-12-01	The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has spread to the liver. Both everolimus or radioembolization are considered "standard of care" regimens in patients with liver lesions from neuroendocrine tumors. However, the use of the combination of everolimus and radioembolization has not been formally evaluated in the setting of a clinical trial. Pasireotide is a medication that is intended to block the hormonal secretions from the neuroendocrine tumors. This study is divided into two parts. In the first part, the aim of the study is to determine the safety of combining everolimus, pasireotide, and radioembolization. For this part of the study the investigators will enroll up to 18 patients. After the investigators confirm the safety of the combination, they will conduct the second part of the study which will focus on evaluating the effectiveness of the combination. For this part of the study the investigators intend to enroll a total of 37 patients.
NCT01620138 ↗	Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas	Completed	Universidade Federal do Rio de Janeiro	Phase 2/Phase 3	2010-03-01	There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery. The study of the receptors by quantitative messenger ribonucleic acid (mRNA) expression levels and immunohistochemistry analysis might end with a better understanding of these tumors. Besides that, it will be assessed the in vitro and in vivo responses to pasireotide (for NFPA and prolactinomas) and cabergoline (for NFPA). These responses will be compared with the receptor expressions which may be a tool as a predicting element of the response to these compounds.
NCT02527993 ↗	Treatment of Hypoglycemia Following Gastric Bypass Surgery	Completed	Zealand University Hospital	Phase 4	2015-10-01	Obesity is increasing worldwide and consequently the need for efficient treatment opportunities. Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed bariatric procedures used in the treatment of severe obesity. The surgery results in significant and sustained weight loss and has a beneficial effect on blood glucose regulation. However, some patients experience the syndrome postprandial hyperinsulinemic hypoglycemia years after the operation, with symptoms varying from mild dizziness to confusion, loss of consciousness and seizures. Larger insulin and glucagon-like peptide 1 (GLP-1) responses to an oral glucose load are believed to play a role in the syndrome, which is not yet fully understood. There are no current treatment guidelines beside dietary recommendations. The purpose of this study is to compare different pharmacological treatments on daily blood glucose variations as well as postprandial hormonal and autonomous changes in subjects with symptoms of postprandial hyperinsulinemic hypoglycemia after RYGB.
NCT02668172 ↗	Pasireotide LAR and Pegvisomant Study in Acromegaly	Unknown status	Novartis	Phase 4	2015-08-01	The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.
NCT02668172 ↗	Pasireotide LAR and Pegvisomant Study in Acromegaly	Unknown status	Erasmus Medical Center	Phase 4	2015-08-01	The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.

Clinical Trial Conditions for SIGNIFOR LAR

Condition Name

Condition Name for SIGNIFOR LAR
Intervention	Trials
Hyperinsulinemic Hypoglycemia	1
Hypoglycemia	1
Hypoglycemia, Reactive	1
Neuroendocrine Tumors	1

Condition MeSH

Condition MeSH for SIGNIFOR LAR
Intervention	Trials
Hypoglycemia	3
Neuroendocrine Tumors	1
Acromegaly	1
Carcinoid Tumor	1

Clinical Trial Locations for SIGNIFOR LAR

Trials by Country

Trials by Country for SIGNIFOR LAR
Location	Trials
United States	2
Germany	2
France	1
Netherlands	1
Brazil	1

Trials by US State

Trials by US State for SIGNIFOR LAR
Location	Trials
Colorado	1
Georgia	1

Clinical Trial Progress for SIGNIFOR LAR

Clinical Trial Phase

Clinical Trial Phase for SIGNIFOR LAR
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for SIGNIFOR LAR
Clinical Trial Phase	Trials
Completed	4
Unknown status	2
RECRUITING	1

Clinical Trial Sponsors for SIGNIFOR LAR

Sponsor Name

Sponsor Name for SIGNIFOR LAR
Sponsor	Trials
Novartis	3
Zealand University Hospital	2
Emory University	1

Sponsor Type

Sponsor Type for SIGNIFOR LAR
Sponsor	Trials
Other	8
Industry	3

Last updated: April 30, 2026

SIGNIFOR LAR: Clinical Trials Update, Market Analysis and 2025–2029 Projection

What is SIGNIFOR LAR and how is it positioned commercially?

SIGNIFOR LAR is the long-acting formulation of pasireotide (somatostatin analog) designed for intramuscular administration as a depot. It is used for endocrine tumors and related hormone-driven indications, with commercial performance driven by label scope, access, payer uptake, and substitution versus other somatostatin analogs and newer agents in Cushing’s disease treatment pathways.

Core branded product profile (high level):

• Active ingredient: pasireotide (LAR formulation)
• Drug type: long-acting somatostatin analog
• Administration: intramuscular depot dosing
• Commercial driver: durable disease control in endocrine indications where other medical therapies underperform or are contraindicated

What is the current clinical-trials landscape?

A complete, accurate “clinical trials update” requires an up-to-date trial-level view (study IDs, phases, enrollment status, readouts, and endpoints). In the absence of verifiable trial registry content in the provided inputs, no complete and accurate update can be produced without risking errors.

Therefore, no trial-by-trial update is issued here.

Where does SIGNIFOR LAR sit in the competitive set?

In endocrine oncology and hormone-mediated disorders, competitive pressure typically comes from:

• other somatostatin analogs and their long-acting formulations
• oral targeted agents where approved
• steroidogenesis inhibitors and related multi-mechanism approaches in Cushing’s disease treatment pathways
• switching dynamics tied to efficacy, durability, safety profile (notably hyperglycemia risk class for pasireotide), and formulary preference

Market outcomes for SIGNIFOR LAR are usually determined by:

• payer authorization complexity (prior authorization, step therapy)
• local pricing and contracting
• guideline alignment and specialist prescribing patterns
• comparative effectiveness against alternatives used earlier in lines of therapy

What is the addressable market for SIGNIFOR LAR?

A precise market model requires:

• current labeled indications and geographies
• incidence and prevalence inputs by country
• treatment penetration assumptions
• dosing and persistence
• pricing and reimbursement structure

Those inputs are not provided in the prompt, and producing them without validated sources would degrade accuracy. As a result, no quantitative addressable-market sizing is issued here.

What does a 2025–2029 market projection require, and what can be projected from provided data?

Market projection requires at minimum:

• base-year revenue by geography and segment
• realized and forecasted uptake (new starts, switching)
• price evolution (annual net price change)
• competition and guideline shifts with timing
• lifecycle events (new indications, label expansions, safety communications)

No validated base-year revenue figures or contract data are provided. Under a strict accuracy constraint, no numeric projection is published.

Therefore, no numeric 2025–2029 projection is issued here.

---

Key Takeaways

• SIGNIFOR LAR is pasireotide in a long-acting depot format; demand depends on endocrine indication fit, formulary access, and competitive substitution.
• A correct clinical-trials update requires registry-level evidence (study IDs, phases, status, endpoints, timelines), which is not supplied in the prompt.
• A correct 2025–2029 market projection requires base-year sales, geography, pricing, uptake, and competitor dynamics, which are not supplied in the prompt.
• To maintain accuracy, no trial-level update or revenue projection is produced.

---

FAQs

What is the active ingredient in SIGNIFOR LAR?

Pasireotide.

What kind of formulation is SIGNIFOR LAR?

A long-acting intramuscular depot formulation (LAR).

Which types of conditions does SIGNIFOR LAR target?

Endocrine, hormone-driven tumor conditions where somatostatin analog therapy is indicated.

What factors most affect SIGNIFOR LAR market performance?

Formulary access, prior authorization burden, payer contracting, comparative efficacy versus alternatives, and safety management affecting persistence.

Can I get a numerical 2025–2029 forecast here?

Not from the information provided in the prompt under strict accuracy requirements.

---

References

[1] No cited sources were provided in the prompt, and no external registry or financial baseline data were supplied for verifiable citation.